Many primary-tumor subregions have low levels of molecular oxygen, termed hypoxia.
INTRODUCTION
The Nobel Prize in Physiology or Medicine for 2019 was awarded for the discoveries of how cells sense and adapt to oxygen availability. Human cells undergo fundamental shifts in gene expression when there are changes in the oxygen (O 2 ) levels around them 1 . These changes in gene expression alter tissue remodeling, cell metabolism, and even organismal responses such as increases in heart rate and ventilation. In 1990's, the Hypoxia Inducible Factor (HIF) was identified, purified and cloned. HIF is a transcription factor that regulates these oxygendependent responses and consisted of two components: HIF-1α and ARNT [2] [3] [4] . In 1995, the von Hippel-Lindau (VHL) tumor suppressor gene was studied and the first full-length clone of the gene was isolated [5] [6] [7] [8] . Consequently, it was demonstrated in 1999 that VHL regulates HIF-1α post-transcriptional and oxygen-sensitivity degradation 9, 10 .
Molecular O 2 is a key nutrient required for aerobic metabolism to maintain intracellular bioenergetics and as a substrate in numerous organic and inorganic reactions. Hypoxia occurs in a variety of physiological as well as pathological conditions 11 . Half of all solid tumors are characterized by dynamic gradients of O 2 distribution and consumption, that is, the tumor environment presents hypoxia subregions due to changes in tumor metabolism that increases O 2 demand or irregular tumor vasculature that decreases O 2 supply [12] [13] [14] [15] [16] [17] [18] . Tumor adaptation to this imbalance between O 2 demand and supply is associated with increased genomic instability and poor clinical prognosis 15, 19 , development of tumor stem cell-protective niches 20, 21 , resistance to radio-and chemotherapy 22, 23 , and increased proclivity for distant metastasis [24] [25] [26] .
Metastasis is thought to be the ultimate manifestation of a neoplastic cell's evolution towards becoming autonomous from the host, and remains the main cause of cancer-related death 27, 28 .
The persistence and lethal relapse of disseminated cancer is driven by stem-like cells that have the ability to regenerate tumors in distant sites [29] [30] [31] [32] . In fact, cure of most cancers is probable whenever diagnosis occurs before cells have spread beyond the tissue of origin; otherwise, cancer is often referred to as incurable [33] [34] [35] . According to Welch and Hurst 28 , the four hallmarks of metastasis are motility and invasion, modulate microenvironment, plasticity and colonization. Regarding mechanisms of HIF-mediated metastasis, hypoxia and activation of HIF signaling influence multiple steps within the metastatic cascade, including invasion and migration, intravasation and extravasation, and establishment of the premetastatic niche, as well as survival and growth at the distant site 24, 36, 37 .
Although hypoxia is an adverse and targetable prognostic feature in multiple cancer types 38, 39 , both the protein-protein interactome (PPi) network and the shortest paths from hypoxia-related genes (HRG) to metastasis had not been described. To fill this gap, we evaluated 233 HRG in 6,343 tumors representing 17 different cancer types. We analyzed genomic alterations and Buffa hypoxia scores per tumor stage, metastatic status and ethnicity across multiple tumor types. We analyzed functional enrichment analysis of hypoxic genes. Lastly, we detailed all information about clinical trials.
RESULTS

OncoPrint of genomic alterations
We analyzed genomic alterations of 6,343 individuals with 17 different cancer types taken from the Pan-Cancer Atlas (PCA) project from The Cancer Genome Atlas (TCGA) [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . Figure 1A shows the OncoPrint of genomic alterations (mRNA high, mRNA low, copy number variant (CNV) deep deletion, CNV amplification, fusion gene, inframe mutation, truncating mutation and missense mutation) of the 233 hypoxia-related genes using cBioPortal 50, 51 . The We found 100,643 genomic alterations in 6,343 individuals. The genomic alteration with the highest frequency mean was mRNA high (0.047), followed by CNV amplification (0.010), mRNA low (0.004), putative driver mutation (0.003), CNV deep deletion (0.003) and fusion gene (0.0004) ( Figure 1B and Table S1 ).
Consequently, genes with the highest frequency mean per genomic alteration were COPS5 (0.204), ELOC (0.175), ARNT (0.137), PIK3CA (0.135) and TFRC (0.117) with mRNA high; SMAD4 (0.081), MAPK1 (0.044), TP53 (0.034), ELF2 (0.031) and AKT1 (0.031) with mRNA low; PIK3CA (0.064), NDRG1 (0.059), TFRC (0.054), ANGPT1 (0.053) and ARNT (0.049) with CNV amplification; STC1 (0.035), ANGPT2 (0.034), SMAD4 (0.021), TEK (0.016) and VEGFC (0.015) with CNV deep deletion; TP53 (0.391), PIK3CA (0.134), SMAD4 (0.029), VHL (0.026) and CDH1 (0.023) with putative driver mutations; ERBB2 (0.006), PRKCA (0.004), TP53 (0.002), CREBBP (0.002) and STAT3 (0.002) with fusion genes; finally, TP53 (0.476), PIK3CA (0.341), COPS5 (0.246), ELOC (0.213) and ARNT (0.198) with all genomic alterations ( Figure   1C and Table S1 ). Figure 2B ). Figure 3A shows the frequency mean of genomic alterations of 17 TCGA Pan-Cancer types per tumor stage. The frequency mean of T1 stage was 0.060 (n = 1,396), of T2 stage was 0.072 (n = 2,306), of T3 stage was 0.068 (n = 2,029), and of T4 was 0.072 (n = 612) (Table S19-S22). The
Genomic alterations per TCGA Pan-Cancer type
Tumor stage and metastasis status
Mann-Whitney U test showed a significant difference of genomic alterations between T1 and T4 stages (P < 0.001). Figure 3B shows the association between genomic alterations and the tumor stage with the highest frequency mean. T2 presented the highest frequency mean of CNV amplifications (0.012), CNV deep deletions (0.004) and fusion genes (0.0004); T3 presented the highest frequency mean of mRNA low; and T4 presented the highest frequency mean of mRNA high (0.050) and putative driver mutations (0.004).
On the other hand, figure 3C shows the frequency mean of genomic alterations per metastasis status. The frequency mean of M0 was 0.069 (n = 4,254) and of M1 was 0.072 (n = 263) ( Table   S23 ). The Mann-Whitney U test showed a significant difference of genomic alterations between M0 and M1 (P < 0.001).
Hypoxia score
We first quantified tumor hypoxia in 5,249 tumors from 13 tumor types in the PCA and TCGA by using Buffa signature 52 . Figure 4A 
Protein expression analysis
The Human Protein Atlas (HPA) presented a map of the human tissue proteome based on tissue microarray-based immunohistochemistry. HPA has analyzed 175 of 233 hypoxia-related proteins across 15 cancer types, classifying the protein expression in high, medium, low and non-detected [53] [54] [55] . As results, AKT3, CAMK2A, PDHA1, PDHB, POLR2A, SMAD4 and SOD3 were proteins with high and medium expression in normal tissues, and non-detected expression in a consensus of 15 cancer types, acting as tumor suppression proteins. Meanwhile, ADAM8, BBC3, CCL2, CDH1, CLDN3, EDN1, EIF4EBP1, RELA and TNC were proteins with high and medium expression in a consensus of 15 cancer types, and non-detected expression in normal tissues, acting as oncogenes ( Figure 5 and Table S24 ). 
Hallmarks of cancer
Protein-protein interactome network
The PPi network was performed to better understand the behavior of hypoxia-related proteins in cancer and metastasis using the String Database and Cytoscape (Figure 7 (Table S25 ). Additionally, top ten proteins with the highest degree centrality in the HIF-1 signaling pathway were AKT1, PIK3CA, HIF1A, VEGFA, EGFR, EP300, CREBBP, STAT3, On the other hand, the Human Cancer Metastasis Database (HCMDB) is an integrated database designed to analyze large scale expression data of cancer metastasis 59 . Our PPi network was conformed by 179 (62%) metastatic driver proteins ( Figure 7 ) (Table S26 ). The top tenmetastasis driver proteins with the highest centrality degree were TP53, AKT1, PIK3CA, HIF1A, VEGFA, EGFR, RAC1, HRAS, EP300 and STAT3.
Functional enrichment analysis using g:Profiler g:Profiler searches for a collection of proteins representing pathways, networks, gene ontology (GO) terms and disease phenotypes such as cancer 60, 61 . Figure 8A shows the enrichment map of the 233 hypoxia-related proteins. The most significant GO: molecular functions with Benjamini-Hochberg correction and false discovery rate (FDR) < 0.001 were phosphotransferase activity, kinase activity, enzyme binding, signaling receptor binding and small molecule binding. The most significant GO: biological processes were response to hypoxia, response to decreased oxygen levels, response to oxygen levels, response to abiotic stimulus and response to stress. Lastly, the most significant signaling pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) were HIF-1 signaling pathway, ErbB signaling pathway, PI3K-Akt signaling pathway, FoxO signaling pathway and mTOR signaling pathway (Table S27 ).
On the other hand, figure 8B shows the enrichment map of 285 proteins conformed by the interaction between hypoxia-related proteins and cancer driver proteins. Phosphotransferase activity, kinase activity, enzyme binding, signaling receptor binding and small molecule binding were the most significant GO: molecular functions. Cellular response to chemical stimulus, response to oxygen levels, response to decreased oxygen levels, response to hypoxia and response to abiotic stimulus were the most significant GO: biological processes. Finally, HIF-1 signaling pathway, pathways in cancer, PI3K-Akt signaling pathway, ErbB signaling pathway and FoxO signaling pathway were the most significant KEGG pathways (Table S28 ).
Shortest paths from hypoxia-related proteins to metastasis
We analyzed the 233 hypoxia-related proteins by using CancerGeneNet software in order to find the shortest paths to metastasis according to Iannuccelli et al 62 (Table S30) . Additionally, 27 (12%) of them presented a frequency mean of genomic alterations more than the average (> 0.068) across 17 TCGA Pan-Cancer types (Table S1) . Figure 11 shows the current status of clinical trials of drugs focused on metastasis according to the Open Targets Platform 63 . There were 31 drugs that were being analyzed in 161 clinical trials in 13 of 62 genes. Cancer types with clinical trials focused on metastasis were breast cancer, kidney cancer, liver cancer, colorectal cancer, melanoma and prostate cancer ( Figure   11A ). EGFR presented the highest number of clinical trials in process, recruiting or completed, followed by FLT1, TEK, ERBB2, IGF1R, PIK3CA, PIK3CG, AKT1, AKT2, AKT3, BCL2, NOTCH1 and TGFBR1 ( Figure 11B ). Most clinical trials were in phase 2, followed by phase 1 and 4 ( Figure 11C ). Antibodies and small molecules were the type of drugs focused on metastasis with 86 and 75 clinical trials, respectively ( Figure 11D ). Inhibition was the most frequent type of action (165), followed by antagonism (5) ( Figure 11E ). Tyrosine protein kinase EGFR family was the target class with highest number of clinical trials (94), followed by tyrosine protein kinase VEGF family (36) , tyrosine protein kinase Tie family (15) , enzyme (6), tyrosine protein kinase InsR family (4), AGC protein kinase AKT family (3), Bcl-2 family (1) and TKL protein kinase STKR type 1 subfamily (1) ( Figure 11F ). Figure 11G diagrams a Sankey plot comparing the number of clinical trials in metastatic drugs analyzed in different cancer types ( Table S31 shows the list of clinical trials of drugs focused on metastasis). Lastly, figure S1 and table S32 shows the list of clinical trials in the entire hypoxia-related genes.
Hypoxic proteins related to metastasis
Clinical trials
DISCUSSION
Hypoxia induces a series of biological changes that contribute to tumorigenesis and metastasis 24, 64 , and are associated with resistance to chemotherapy, radiation therapy, drug therapy and immunotherapy. Therefore, understanding the effect of hypoxia on multi-omics signatures is crucial to improving the outcomes of cancer therapy 65 .
We analyzed the OncoPrint of 100,643 genomic alterations (233 HRG) Regarding genomic alterations per tumor stage across 17 TCGA Pan-Cancer types, T4 stage showed the highest frequency mean (0.072), followed by T2, T3 and T1. There was a significant difference (Mann-Whitney U test, P < 0.001) between T1 and T4 stages. In addition, T4 stage presented the highest frequency means of mRNA high alteration (0.050) and putative driver mutations (0.004). On the other hand, the frequency mean of genomic alterations in HRG was higher in patients with metastasis (0.072) than in patients without metastasis (0.069), with a significant difference (Mann-Whitney U test, P < 0.001). That is, the amount of genomic alterations in the HRG increases as the tumor stage and metastasis status evolves.
In order to validate the significant differences of genomic alterations of HRG found in T stages and metastasis status, we analyzed the Buffa hypoxia score across 13 TCGA Pan-Cancer types.
The Buffa signature is an approach for deriving signatures that combine knowledge of gene function and analysis of in vivo co-expression patterns. Hypoxia scores were estimated by obtaining the mean expression (log2) of 52 hypoxia genes reported by Buffa et al 52, 68 . Cancer types with the highest HS mean were HNSC, LUSC, CESC, CRC and BLCA, and the overall HS mean was 0.85. Regarding T stages, T4 presented the highest HS mean (14.5), followed by T2, T3 and T1. There was a significant difference (Mann-Whitney U test, P < 0.001) between T1 and T4 stages. On the other hand, the Buffa HS mean in patients with metastasis (8.3) was higher than in patients without metastasis (2.2), with a significant difference (Mann-Whitney U test, P < 0.001). In regard to ethnicity, Guerrero et al., indicate a need to diversify oncological studies to other populations along with novel strategies to enhance race/ethnicity data recording and reporting 69 . In this context, Black / African Americans showed highest HS mean (4.4) than Whites and Asians, and Black /African Americans with metastasis showed highest HS mean In addition to analyzing the genomics and transcriptomics of HRG, we evaluated the human tissue proteome based on tissue microarray-based immunohistochemistry of 175 hypoxiarelated proteins across 15 TCGA Pan-Cancer types [53] [54] [55] 67 . The AKT3, CAMK2A, PDHA1, PDHB, POLR2A, SMAD4 and SOD3 proteins acted as tumor suppressors, meanwhile, the ADAM8, BBC3, CCL2, CDH1, CLDN3, EDN1, EIF4EBP1, RELA and TN proteins acted as oncogenes according to the expression levels between normal and tumor tissues.
Regarding the hallmarks of cancer proposed by Hanahan and Weinberg 56 , 23 of 230 HRG showed some of these cancer features. The TP53, AKT1, EGFR, EPAS1, HIF1A, MTOR, NOTCH1, VHL, CREBBP and ERBB2 genes presented the highest number of associations with these hallmarks. Invasion and metastasis was promoted by TP53, AKT1, EGFR, EPAS1, HIF1A, MTOR, VHL, CREBBP, ERBB2, NDRG1, PIK3CA, PLCG1, SMAD3, ARNT, MAPK1, PIK3R1, ATP1A1, CDH1 and CXCR4; suppressed by TP53, VHL, NDRG1, ARNT and PIK3R1; finally, promoted and suppressed by AKT1 and CDH1.
It is important to mention that proteins do not work alone, that is why we performed a proteinprotein interactome network analysis to better understand the behavior of hypoxia-related proteins and its correlation with cancer driver proteins and metastasis. The PPi network had 285 nodes conformed by 163 (57%) hypoxic proteins, 98 (34%) cancer driver proteins, and 24 cancer driver proteins with hypoxic signature. Regarding metastasis, our PPi network was conformed by 179 of 285 (62%) metastatic driver proteins. The top ten-metastasis driver proteins with the highest centrality degree were TP53, AKT1, PIK3CA, HIF1A, VEGFA, EGFR, RAC1, HRAS, EP300 and STAT3.
Consequently, we performed two functional enrichment analyses by using g:Profiler 60 . The first analysis was conformed by the 233 hypoxia-related proteins where the most significant (FDR < 0.001) GO: biological processes were response to hypoxia, response to decreased oxygen levels, response to oxygen levels, response to abiotic stimulus and response to stress. The most significant KEGG signaling pathways were HIF-1, ErbB, PI3K-Akt, FoxO and mTOR. As expected, all terms were related to hypoxia conditions. The second analysis showed the enrichment map of 285 proteins conformed by the interaction between hypoxia-related proteins and cancer driver proteins. The most significant GO: biological processes were cellular response to chemical stimulus, response to oxygen levels, response to decreased oxygen levels, response to hypoxia and response to abiotic stimulus. Finally, HIF-1, PI3K-Akt, ErbB and FoxO were the most significant KEGG signaling pathways.
Another way to analyze the correlation between hypoxia and metastasis was unrevealing the shortest paths from hypoxia-related proteins to metastasis signaling 62 . We found that 99 of 233 (42%) proteins had paths to metastasis where 49 had positive regulation with an average distance of 3.0, and 16 had negative regulation with an average distance of 3.5. Hypoxic proteins with the shortest distance to metastasis were BACH1, AKT2, AKT1, CAMK2B, EGFR, MAPK1, MAPK3, PRKCA, PRKCB and EGF. Lastly, these 99 hypoxia-related proteins send metastatic signaling through CTNNB1, BACH1, EZR, PTTG, WASF3 and NFE2L2.
After the PPi network analysis and the analysis of the shortest paths to metastasis, we proposed 62 proteins with the highest affinity to metastasis phenotype (Figure 10 ). Of them, 27 proteins presented a frequency mean of genomic alterations more than the average (> 0.068) across 17 TCGA Pan-Cancer types. Consequently, we observed that 13 of these 62 proteins have 31 drugs studied in 161 clinical trials focused on metastasis. It is important to mention that the percentage of druggable proteins under clinical trials is low and machine-learning analysis could be required in order to improve the selection of drugs against metastasis 70,71 .
CONCLUSIONS
Hypoxia and HIF-dependent signaling play an important role in metastasis tumor progression.
The hypoxic tumor microenvironment influences both the early and late stages of metastasis.
Our study provides a comprehensive view of multi-omics analyses in hypoxia-related genes.
Our findings suggest that individuals with metastasis present highest frequency of genomic alterations and hypoxia score across 17 TCGA Pan-Cancer types. The most altered pathways where hypoxic genes are involved are HIF-1, ErbB, PI3K-Akt, FoxO, mTOR and Ras signaling pathways. The analyses of both the PPi network and the shortest paths to metastasis suggest 62 proteins strongly related to metastasis. Finally, there are few drugs anti-metastasis that are being studied in clinical trials so far. Hence, it is imperative to focus our strengths in drug developing and drug discovery to improve precision medicine and find effective therapies anti-metastasis.
METHODS
Dataset of hypoxia-related genes
In this study we analyzed a dataset of 233 HRG curated manually. 109 of them conformed the KEGG HIF-1 signaling pathway 72 , 102 of them were involved in some of the GO terms related to hypoxia: response to hypoxia, cellular response to hypoxia and cellular response to decreased oxygen levels by using g:Profiler 60 , 52 of them were hypoxia genes according to Buffa et al 52 , and 75 of them underlie high-altitude adaptive phenotypes in populations from the Andean Altiplano, Semien Plateau and the Tibetan Plateau, according to Bigham 73 .
Genomic alterations
Genomic alterations (mRNA high, mRNA low, CNV deep deletion, CNV amplification, fusion gene, inframe mutation, truncating mutation and missense mutation) were analyzed in 6,343 tumors (all with tumor stage) from 17 TCGA Pan-Cancer types (BLCA, BRCA, CESC, CRC, ESCA, HNSC, KIRC, LIHC, LUAD, LUSC, MESO, PAAD, PRAD, SKCM, STAD, TGCT and THCA). Genomics and clinical data related to tumor stage (T1-T4) and metastasis status (M0-M1) was taken from the Genomics Data Commons of the National Cancer Institute (https://portal.gdc.cancer.gov/) and the cBioPortal (http://www.cbioportal.org/) 50, 51 .
Hypoxia score
The Buffa hypoxia score was analyzed in 5,249 tumors from 13 TCGA Pan-Cancer types (HNSC, LUSC, CESC, CRC, BLCA, SKCM, KIRC, LUAD, PAAD, BRCA, LIHC, PRAD and THCA) 52 . An approach for deriving signatures that combine knowledge of gene function and analysis of in vivo co-expression patterns was used to define a common hypoxia signature in cancer. Hypoxia scores were estimated by obtaining the mean expression (log2) of 52 hypoxia genes reported by Buffa et al 52, 68 .
Data related to Buffa hypoxia score, tumor stage, metastasis status and ethnicity (black / African American, white and Asian) was taken from the Genomics Data Commons and the cBioPortal 50, 51 . Lastly, the Mann-Whitney U test was performed to determine significant differences between hypoxia score and clinical data.
Protein expression analysis
The Human Protein Atlas (https://www.proteinatlas.org/) explains the diverse molecular signatures of proteomes in the human tissue based on tissue microarray-based immunohistochemistry 53, 54, 74, 75 . We compared the protein levels (high, medium, low, nondetected) of our 175 proteins between normal tissues and tumor tissues from 15 different cancer types. Lastly, we obtained a list of proteins with potential interaction as oncogenes and tumor suppressor genes.
Protein-protein interactome network
The PPi network with a highest confidence cutoff of 0.9 and zero node addition was created using the String Database, which takes into account predicted and known interactions 57, 76, 77 .
The degree centrality of a node means the number of edges the node has to other nodes in the network. Metastasis driver proteins that interact with the hypoxia-related proteins were taken from the Human Cancer Metastasis Database (https://hcmdb.i-sanger.com/). HCMDB is an integrated database designed to analyze large scale expression data of cancer metastasis 59 . The network visualization was analyzed through the Cytoscape software 58 . Hypoxia-related proteins, cancer driver proteins, metastasis driver proteins, and significant signaling pathways (P < 0.001) were differentiated by colors in the PPi network.
Functional enrichment analysis using g:Profiler
The enrichment analysis gives scientists curated interpretation of gene/protein lists from genome-scale experiments 60 . The hypoxia-related proteins and cancer driver proteins were analyzed by using g:Profiler (https://biit.cs.ut.ee/gprofiler/gost) in order to obtain significant annotations (Benjamini-Hochberg (FDR) < 0.001) related to GO terms (molecular functions and biological processes), and KEGG signaling pathways 60, 72 .
Shortest paths from hypoxia-related proteins to metastasis
CancerGeneNet (https://signor.uniroma2.it/CancerGeneNet/) is a resource that links genes that are frequently mutated in all cancer types to cancer phenotypes. This resource is based on the annotation of experimental information that permits to embed the cancer genes into the cell network of causal protein relationships curated in SIGNOR 78 . Consequently, this bioinformatics tool allows to infer likely paths of causal interactions linking cancer associated genes to cancer phenotypes such as metastasis 62 . Iannuccelli et al explained that the shortest paths between a specific gene and cancer phenotypes was programmatically implemented using the shortest path function of the R igraph, obtaining a distance score and a path length score 62, 79 . Hence, we analyzed the shortest paths from our hypoxia-related proteins to metastasis to better understand the association to this hallmark of cancer 62, 80 .
Clinical trials
The Open Targets Platform (https://www.targetvalidation.org) is comprehensive and robust data integration for access to and visualization of potential drug targets associated with several cancer types and metastasis. Additionally, this platform shows all drugs in clinical trials associated with biomarkers or cancer genes, detailing its phase, type of drug, action type, and target class 63 . 
Figure legends
